raise in elderly patients with suppressed serum TSH levels. Moreover, the effects on thyroid volume and nodules size, monitored by ultrasonography (US), are limited (e.g. studies of Cheung et al. and Jarlov et al. [10, 11] ).
However, the majority of clinical studies enrolled patients affected by uninodular non-toxic goiter (UNG), whereas only few controlled trials were carried out on non-toxic MNG [3, [12] [13] [14] [15] [16] [17] [18] [19] . The abovementioned trials, not uniform for patients selection, therapeutic approach and thyroid/nodules changes evaluation, show that the effect of L-T 4 is at best very modest and a sufficient goiter reduction can only be expected in a minority of patients in addition to possioriginal of variation for repeated measurements in the same patients was 7%, thus we considered volume changes exceeding this value to be clinically significant. The following reference values were obtained measuring the thyroid volume on 100 healthy female subjects (age 18-55 years, weight 38-80 kg, no history of thyroid disorders, fT 3 , fT 4 and TSH serum levels within the normal range): mean dimension 9.0 ± 2.9 mL, median 8.9 [3.5-14.4 ] mL, 5°-100° percentile 4.6-14.4 mL.
We differentiated thyroid nodules with a volume cut-off of 0.5 mL corresponding to 1 cm diameter (volumes were calculated according to the ellipsoid formula (height x width x depth x 0.529 [20] ) after fine needle aspiration procedure). The applied correction factor is the optimal coefficient derived from correlation of the ellipsoid formula to MDCT images [20] . A thyroid volume higher than 14.5 mL was considered indicative of goiter.
Laboratory findings
Serum TSH, fT 4 , fT 3 , thyroglobulin, TgAb and TPOAb levels were measured by immunochemiluminescence assay (Modular E170 Analyzer, Roche). Morning casual urinary samples were used for the measurement of iodine concentration by the method of Sandell-Kolthoff and the results were expressed as micrograms of iodine / urine litre [21] .
A thyroid scan with 99mTc pertechnetate and 131 I uptake (normal values, 10-40% at 6 h and 15-60% at 24 h) were performed with a γ-camera (Philips, The Netherlands).
Statistical analysis
All data were first analyzed for normality of distribution using the Kolmogorov-Smirnov test of normality. When comparing differences among groups, the Mann-Whitney or Kruskal-Wallis non parametric test was used for non-normally distributed continues variables (thyroid volume, dominant nodule mean volume, number of nodules) and unpaired t-test or repeated measurements ANOVA was used for normally distributed variables (age, TSH,.fT 3 and fT 4 ) as appropriate. Data are presented as mean ± SD or frequency; median and range are added for non normally distributed variables, The distribution frequency of volume changes and of new nodules development in the two groups was compared by χ 2 and Fisher exact tests. The significance level was set at p=0.05. ble toxic effects.
The present study evaluated, in a homogeneous group of pre-menopausal women, affected by thyroid multinodular disease (TMD), not necessarily MNG, and randomly assigned to L-T 4 suppressive therapy or to a control group, over a 24-months period: 1) changes in thyroid volume and in nodules number and size; 2) correlations among baseline size, clinical and laboratory parameters, degree of TSH suppression, and observed thyroid/nodules changes.
Materials and Methods

Study design
The study was a prospective randomized clinical trial. Seventy-one consecutive pre-menopausal women patients from Latina, an area of iodine deficiency, were randomly assigned to a L-T 4 (2 μg/kg body weight) treated group or to a non-treated control group. Entry criteria included: ultrasonography characteristics of thyroid multinodular disease (2-5 nodules); cytology on dominant or suspicious nodule consistent with a colloid pattern by fine needle aspiration; 99mTC scan consistent with hypofunctioning or non-visualized nodules; no cystic or mixed nodules with fluid area higher than 30%; normal levels of serum TSH, fT 4 , fT 3 and absence of antithyroglobulin (TgAb) and antithyroid peroxidase (TPOAb) antibodies; no previous treatment with thyroid hormones, iodine compounds or antithyroid drugs; no smoking history; no pregnancy in the last 12 months, Body Mass Index between 18.5 and 30, no history of neck irradiation or surgery.
The study was conducted according to the principles of the Helsinki declaration after approval by the local institution review board and written informed consent was obtained from all subjects.
Protocol
Clinical and hormonal evaluations were unblended, whereas US scans were blinded performed. Forty-one patients were followed for 24 months and the obtained results prompted us to stop the observation period after 12 months for the remaining subjects. Sonograms and hormonal profiles were performed at 0, 6, 12, 24 months, urinary iodine determination and scintiscans only at the enrolment. All subjects underwent US evaluations in the same centre by a single examiner with a real time instrument (Aloka, Italy), using a high resolution 10-Megahertz near probe. The coefficient mL). Conversely, no changes were observed in the control group, which remained within the normal range throughout the study period.
fT 3 and fT 4 levels in the L-T 4 treated group didn't present any variation in the first 6 months of therapy, but a significant increase, not exceeding normal values range, from 2.7 ± 0.6 and 1.19 ± 0.22 pg/mL to 2.9 ± 0.6 and 1.36 ± 0.24 ng/dL respectively, was observed from the 6 th to the 12 th month (p=0.033 and p<0.001). On the other hand, the control group didn't show any change in fT 3 levels during the follow-up period whereas fT 4 increased without exceeding reference values.
As assessed by ultrasonography, in the L-T 4 treated group, thyroid volume significantly decreased from 15.6 ± 11.3 (median 12 [5.5-54] ) to 10.6 ± 4.9 (median 9.8 [4-25.9]) mL (p<0.001) after 1 year of treatment; however at the end of the first 6 months it didn't yet present any change compared to baseline value.
In the same group, a difference (0. 
Results
Seventy-one (36 randomly assigned to the L-T 4 treated group and 35 to the control group), out of a total of 95 enrolled subjects, were followed for one year whereas forty-one (21 in the treated and 20 in the control group) subjects completed the two years observation period. Drop-out patients: 8 subjects underwent surgical treatment (5 in the control and 3 in the L-T 4 treated group); 13 patients (5 in the L-T 4 treated group and 8 in the control group) abandoned the study and 3 patients of the L-T 4 treated group experienced side-effects (nervousness, tachycardia and headache).
Clinical and laboratory findings of the L-T 4 treated and control groups at baseline are shown in Table 1 .
At the beginning of the study, the two groups were similar for age, clinical and hormonal values (presenting TSH, fT 3 and fT 4 values within the normal range) and thyroid characteristics. In 3 subjects thyroid volume was lower than the reference interval [4.6-14.5 mL, 5°-100° percentile] but within the 1°-5° percentile of healthy subjects distribution; as expected, thyroid size was related to subjects body weight [22] .
In Table 2 are reported changes in hormone levels and thyroid echography characteristics after 6 and 12 months of observation in the L-T 4 treated and in the control groups.
A significant decrease of TSH levels was obtained after the first 6 months in patients receiving levothyroxine treatment (0.2 ± 0.1 vs. 1.9 ± 0.8 μIU/mL; p<0.001); thereafter, TSH suppression was complete and stable for the following 6 months (0.2 ± 0.1 μIU/ 1.2 ± 1.0 1.7 [0. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 0.001
Conversion factors for SI units are: 12.872 for fT 4 (ng/dL in pmol/L) and 1.536 for fT 3 (pg/mL in pmol/L) 1 Healthy thyroid tissue added with nodular parts volume size monitoring. In some of these clinical trials only 20-30% of the patients were regarded as responders to the treatment, but this concerned only thyroid volume, while there weren't any information about reduction of nodules. Moreover, concerns about the risk-benefit ratio of suppressive L-T 4 therapy were raised, because it was associated with a decrease in bone mineral density (as described in the randomized study of Wesche [15] , after evaluation by dual-energy x-ray absorptiometry scanning), and symptoms of thyrotoxicosis with an increased basal metabolism (nervousness, tachycardia, headache, etc.). Recent prospective studies have found a significant nodule volume shrinking [33, 34] or higher frequency of regression [35] after 1 year of TSH suppression. These relatively short trials, focused on nodule size reduction, were inadequate to evaluate the efficacy of L-T 4 treatment in decreasing thyroid volume and number of nodules. Moreover, the mean age of patients was higher than that of ours (about 40% of treatment group was postmenopausal women) and the L-T 4 dose was higher (2.5 mg/kg body weight) than that of our study, aiming at TSH values more suppressed (between 0.01 and 0.1 mIU/L) than ours. Data obtained from these studies also presented many discrepancies due to several factors, including lack of control groups or randomization, treated group's heterogeneity (UNG vs. MNG or UNG vs. TMD), variable doses and duration of therapy, different definitions of response to treatment, differences in level of TSH suppression and in methods used to assess nodule volume.
Papini et al. [29] also conducted a study on the effectiveness of L-T 4 suppressive therapy, but this experimental work (performed in patients with UNG) lasted for a period of 5 years. In this trial, even though TSH suppression failed to induce significant volume reduction in the treatment group as a whole, however it did affect the natural history of thyroid nodules [36] , preventing the significant 5-year volume increase observed in the control group, and reducing the number of growing nodules. However, some lesions remained unaffected by L-T 4 and continued to grow, probably under the influence of local growth factors or growthpromoting mutations. Also in the control group some nodules decreased spontaneously, although much less frequently than in the treatment group.
In our study we evaluated if suppressive levothyroxine therapy in pre-menopausal women affected by TMD is cause of reduction in thyroid volume and in Finally, when considering only the subjects followed for 24 months (see table 3), the variations of biochemical and echography characteristics resemble those observed in the entire population over 1 year period and strengthen the reduction of thyroid volume and nodule volume and number also after 2 years of observation. At the end of the study the presence of the goiter was reduced in the treated group from 29% to 9% whereas an increase from 15% to 40% was observed in the control group.
Discussion
TSH, local growth factors and intrinsic cellular heterogeneity of thyroid cells are related to development of thyroid nodules [23] [24] [25] [26] . The efficacy of TSHsuppressive doses of levothyroxine to reduce the size of thyroid nodules both in goiter and TMD is still controversial [1] [2] [3] [4] . Since the introduction of ultrasonography to monitor thyroid and nodules volume and high-sensitivity TSH assays to verify suppression, several prospective controlled trials of L-T 4 treatment for solitary thyroid nodules were published, with different conclusions [10, [27] [28] [29] [30] [31] . Some studies [27] [28] [29] reported an increased proportion of patients on L-T 4 therapy who presented a 50% reduction of solitary thyroid nodules volume, as compared with the control group. Conversely, other studies did not observe a significant difference [10, 30, 31] . However, these negative trials did not have sufficient statistical power to exclude an effect of the treatment. In 2002, a study of Wémeau et al. [32] demonstrated that 18 months of TSH-suppressive L-T 4 therapy were effective in reducing the growth of solitary thyroid nodules as well as in preventing the further development of additional nodules in patients originating from an area with quite sufficient iodine supply. Nevertheless, many questions remained to be answered, such as the optimal level of thyroid suppression or duration of treatment.
Despite several reports have appeared in scientific literature on the use of L-T 4 for the treatment of UNG, only few recent articles have valuated the efficacy of L-T 4 therapy in patients with TMD. These trials failed to demonstrate a significant reduction in thyroid nodule size [10, 30, 31] ; furthermore, they are discordant, present numerous publication bias and only three controlled studies utilized ultrasonography for objective despite the conflicting results of previous studies, seem to confirm the tendency of benign nodular disease toward progression and the efficacy of TSH suppression in preventing its evolution.
The results of our clinical trial also showed that suppressive L-T 4 therapy significantly reduced thyroid volume just after the first 6 months of therapy confirming L-T 4 treatment's efficacy over a longer period. As a matter of fact, a limitation of our study is due to the short duration of the treatment; however, results observed on the restrict group of patients followed for 24 months strengthen previous conclusions even though we are not able to give reliable information about the long-term L-T 4 therapy efficacy and potential adverse effects.
In conclusion, our study (according to Papini et al. [29] ) suggests that, in pre-menopausal women with TMD still presenting normal TSH levels, the suppression of serum TSH probably remove the major growth stimulator for the large proportion of thyroid nodules still responsive to physiological stimuli, preventing the development of new lesions and increases in nodule and thyroid size. number and/or volume of the nodules in a short period of clinical observation (6, 12 and 24 months). Furthermore, our trial was designed to evaluate both the efficacy of TSH suppression on these parameters compared to the natural history of untreated nodular disease, determining an adequate TSH suppression and detecting the necessary minimum duration of L-T 4 suppressive therapy. We've also eliminated variables that negatively influenced precedent studies (inappropriate methodology, lack of randomization, absence of ultrasonography evaluation, uncontrolled or inefficient TSH suppression, insufficient treatment duration -as Wémeau et al. [32] noted-). We have also analyzed the evolution of nodules worthy of clinical consideration (i.e. nodules > 0.5 mL), that were not adequately pointed out in previous studies and, in order to obtain a complete assessment of treatment with L-T 4 in TMD, we have reported dominant nodule mean volume.
Results of our clinical trial showed that L-T 4 induced a significant reduction in thyroid size and on the other hand, an increase in thyroid dimension was observed in the control group. Moreover, we observed a significant reduction in dominant nodule mean volume and in numbers of nodules of treated patients, whereas in the control group a significant increase of these two parameters became evident. As a whole, these findings support previous observations on the clinical efficacy of long term L-T 4 treatment in preventing thyroid volume and nodule volume/number growth and,
